

Attachment 12: Phase IV Buccal Cell IRB Approval Signature Pages

12.1). Phase IV IRB NCI

12.2). Phase IV IRB Westat

12.3). Phase IV IRB University of Iowa



iRIS Reference Number 320597

Amendment Letter: B
IRB Number: OH93NCN013
Version Date: 02/15/2012

06/07/2012

TO: Michael Alavanja
NCI - Occupational and Environmental Epidemiology Branch

FROM: Chairperson, Special Studies Institutional Review Board, NCI

SUBJECT: Action on Clinical Research Protocol Amendment

Your amendment to protocol, "The Main Agricultural Health Study - A Prospective Study of Cancer and Other Diseases among Men and Women in Agriculture," was reviewed by the National Cancer Institute Special Studies Institutional Review Board (NCI-SSIRB) by expedited review.

The SSIRB has taken the following action:

X	Approved as written. Forwarded to the CC OPS for administrative processing.
	Approved with stipulations pending re-review by SSIRB Chair. See review comments.
	Deferred pending response to stipulations and re-review by a subcommittee of the Board. See review comments.
	Tabled pending response to stipulations and re-review by the full SSIRB. See review comments.



AMENDMENT REVIEW FORM

(TO ADD OR CHANGE PREVIOUSLY APPROVED RESEARCH)

All changes or new activities for previously approved studies require submission, review and approval of an Amendment Request. Please complete and submit this form to irb@westat.com and attach all necessary materials to be reviewed. Once reviewed, you will be contacted. If this change or new activity requires a full Board review, those meetings occur on the second Tuesday of every month. To check the date of meetings, please see the [meeting schedule](#) under IRB in WesInfo. Thank you for your cooperation.

1. Today's Date:	03 / 26 / 2012	
Date of Original Approval:	00 / 00 / 2008	
Project Name:	The Agricultural Health Study	
Westat Project Number:	8970 .	
Agency Grant or Contract Number:	HHSN261201100017C	
Project Director:	Marsha Dunn	Ext. 3557
Unit Ops Number/Study Area:	1.21.72	
Area IRB Rep:	Nancy Weinfield	

2. Indicate the type of addition or change being requested to a previously approved study.

(SELECT ALL THAT APPLY.)

- | | |
|---|--|
| <input type="checkbox"/> Name (s) of investigators | <input type="checkbox"/> Review of final instrument such as interview questions or data collection sites for a previously approved study |
| <input type="checkbox"/> Project Number | <input type="checkbox"/> Mode of administration of instruments in your study (e.g., from mail or telephone to web or Internet access) |
| <input type="checkbox"/> Introduction of a new IRB or request for Westat to serve as the IRB | <input type="checkbox"/> Data access rights |
| <input type="checkbox"/> Study design, survey questionnaire or procedure (s) | <input type="checkbox"/> Any other change in protocol that affects treatment of human subjects: |
| <input checked="" type="checkbox"/> Informed consent process, consent form (s), parent permission (s), or assent form (s) | <i>(PLEASE SPECIFY)</i> |
| <input checked="" type="checkbox"/> Recruitment materials or strategies | |
| <input type="checkbox"/> Incentives | |
| <input type="checkbox"/> Survey instruments | |
| <input type="checkbox"/> Number or type of populations studied | |

IRB Office Only

APPROVED – NEXT CONTINUING REVIEW DATE: _____

CONDITIONAL APPROVAL (PLEASE SEE ATTACHED LETTER)

DID NOT QUALIFY FOR EXPEDITED REVIEW

3. Please provide a brief summary of your change or addition to previously approved research.

In Phase IV we will continue the Phase III buccal collection protocol, which requests buccal specimens from selected cancer cases. Westat will contact the North Carolina cohort and the University of Iowa (subcontractor), the Iowa cohort. Westat will coordinate. See also attached.

4. How does each change or addition affect the risks to participants in your study? (PLEASE SELECT ONLY ONE.)

- a. No change
- b. N/A – no risks
- c. Decreases the risk (SPECIFY):


- d. Increases the risk (SPECIFY):

- e. Adds a new risk (SPECIFY):

SIGNATURE – Sign here or deliver through electronic email from your computer.

The information provided in this request form is complete and correct.

Project Director/Principal Investigator:



Date:

3/26/2012

Please attach:

- One document that clearly identifies (through track changes, highlights, or italics) the revision in the previously approved submission.
- Another document labeled “corrected version.”

If you have any questions, feel free to contact Sharon Zack, IRB Administrator, at ext. 8828.

IRB Administration Use Only

Expedited review and approval for the modification(s) on this form:

IRB Chair / Associate Chair / Designee

Date

IRB Office Only

APPROVED – NEXT CONTINUING REVIEW DATE: _____

CONDITIONAL APPROVAL (PLEASE SEE ATTACHED LETTER)

DID NOT QUALIFY FOR EXPEDITED REVIEW

Protection of Human Subjects
Assurance Identification/IRB Certification/Declaration of Exemption
(Common Rule)

Policy. Research activities involving human subjects may not be conducted or supported by the Departments and Agencies adopting the Common Rule (56FR28003, June 18, 1991) unless the activities are exempt from or approved in accordance with the Common Rule. See section 101(b) of the Common Rule for exemptions. Institutions submitting applications or proposals for support must submit certification of appropriate Institutional Review Board (IRB) review and approval to the Department or Agency in accordance with the Common Rule.

Institutions must have an assurance of compliance that applies to the research to be conducted and should submit certification of IRB review and approval with each application or proposal unless otherwise advised by the Department or Agency.

201202812

1. Request Type <input checked="" type="checkbox"/> ORIGINAL <input type="checkbox"/> CONTINUATION <input type="checkbox"/> EXEMPTION	2. Type of Mechanism <input type="checkbox"/> GRANT <input checked="" type="checkbox"/> CONTRACT <input type="checkbox"/> FELLOWSHIP <input type="checkbox"/> COOPERATIVE AGREEMENT <input type="checkbox"/> OTHER: _____	3. Name of Federal Department or Agency, or organization, and, if known, Application or Proposal Identification No. US Department of Health & Human Services, National Institutes of Health//Westat, Inc. 8970-S01
4. Title of Application or Activity AHS Phase IV Buccal Cell Collection		5. Name of Principal Investigator, Program Director, Fellow, or Other Charles Lynch

6. Assurance Status of this Project (*Respond to one of the following*)


- This Assurance, on file with Department of Health and Human Services, covers this activity:
 Assurance Identification No. FWA00003007, the expiration date 11/08/2013 IRB Registration No. IRB00000099
- Exemption Status: Human subjects are involved, but this activity qualifies for exemption under Section 101(b), paragraph .

7. Certification of IRB Review (*Respond to one of the following IF you have an Assurance on file*)

- This activity has been reviewed and approved by the IRB in accordance with the Common Rule and any other governing regulations.
 by: Full IRB Review -- date of IRB meeting: or Expedited Review
 Approval Date: 03/28/12
 Expiration Date: 03/28/13
- This activity contains multiple projects, some of which have not been reviewed. The IRB has granted approval on condition that all projects covered by the Common Rule will be reviewed and approved before they are initiated and that appropriate further certification will be submitted.

8. Comments

Contract Title: The Agricultural Health Study (AHS) Phase IV

9. The official signing below certifies that the information provided above is correct and that, as required, future reviews will be performed until study closure and certification will be provided.	10. Name and Address of Institution The University of Iowa Human Subjects Office Office of the Vice President for Research 340 Medicine Administration Bldg The University of Iowa Iowa City, IA 52242-1101
11. Phone No. (<i>with area code</i>) 319-335-6564 12. Fax No. (<i>with area code</i>) 319-335-7310 13. Email: James-walker@uiowa.edu	15. Title Associate Vice President for Research - Regulatory Affairs
14. Name of Official James C Walker, PhD	17. Date 03/28/12
16. Signature 	

Authorized for local Reproduction

Sponsored by HHS

Public reporting burden for this collection of information is estimated to average less than an hour per response. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: OS Reports Clearance Officer, Room 503 200 Independence Avenue, SW., Washington, DC 20201. Do not return the completed form to this address.